Methylnaltrexone bromide (Relistor) is approved by the FDA for opioid-induced constipation
Wyeth gets regulatory nod for constipation drug
For late-stage, advanced illness patients who develop constipation due to their need for opioids on a continuous basis, there may now be some relief. Wyeth Pharmaceuticals has announced the approval of methylnaltrexone bromide (Relistor), a new drug that works by blocking opioid entrance into the bowel cells, allowing them to continue to function normally. The new product is administered as needed, but the dose should not exceed one injection in a 24-hour period and should not be used in patients with known or suspected intestinal obstructions. The efficacy and safety of methylnaltrexone was conducted in two studies involving 287 patients over a four-month period. Patients receiving the drug experienced a significantly higher rate of elimination than those receiving placebo.
Pharmacists Play Unique Role in Advancing Health Equity for Patients With Chronic Disease
December 7th 2023A new study, outlined in a poster at ASHP Midyear 2023, identified 3 key themes associated with the ways in which pharmacists are positioned to advance health equity for patients with chronic diseases.
Assessing Financial Impacts of Pharmacist-Led Interventions in Pediatric Ambulatory Care
December 5th 2023According to a poster abstract presented at the ASHP Midyear Clinical Meeting & Exhibition, specialty pharmacy services were used for a variety of conditions that have been reported in adult populations.
